** Shares of drug developer Wave Life Sciences WVE.O rise 4.5% to $10.50 premarket
** Co reports Q4 diluted income per share of 18 cents, compared with loss of 15 cents a year ago
** WVE posts Q4 revenue of $83.7 million vs $29.1 million a year earlier
** As of last close, stock is down 18.8% YTD
(Reporting by Jaiveer Singh Shekhawat in Bengaluru)
((JaiveerSingh.Shekhawat@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.